For early-stage neurotherapeutics companies, momentum is often built through a sequence of reinforcing signals—scientific readiness, experienced leadership, and capital aligned around a clear clinical path. Maryland-founded Higher Medicine is now adding another of those signals with a newly announced strategic investment that advances its push toward first-in-human studies.
The company disclosed a strategic investment from Cerdwen, a West Chester, Pennsylvania–based investor that partners with founders working to translate bold scientific concepts into clinical and commercial impact. The transaction, completed via a Simple Agreement for Future Equity (SAFE), closed on December 31, 2025, and advances Higher Medicine’s Seed Expansion financing as it prepares for IND-enabling work.
“Higher Medicine exemplifies the type of company we seek to partner with: rigorous science, a focused initial indication, and a platform capable of expanding into significant unmet medical needs,” said Kevin Brophy, Managing Principal of Cerdwen. “Dr. Kim and his team are tackling complex CNS disorders with a differentiated epigenetic approach, and we believe the company is well-positioned to translate that ambition into clinical impact.”
A Focused Entry into High-Unmet-Need Brain Disorders
Higher Medicine is advancing clinic-ready small-molecule therapies for pediatric and neurodegenerative disorders, beginning with Kabuki syndrome and Friedreich’s ataxia. Its lead programs—an LSD1 inhibitor and a p38 MAP kinase inhibitor—are supported by substantial existing safety and clinical data, a foundation the company believes enables a de-risked entry into Phase 2a trials by 2026.
Though the investment amount was not disclosed, company previously reported $200,000 raised to date and $2.1 million in soft commitments as it works toward closing a $2 million pre-seed round to complete IND-enabling steps. Beyond its initial indications, Higher Medicine sees its epigenetic platform as extensible across a broader range of CNS conditions, including autism spectrum disorders, Alzheimer’s disease, and other neurodegenerative pathologies.
“Higher Medicine was founded on a simple but ambitious belief: that many devastating brain disorders need not be lifelong sentences,” said Dr. Leo Kim, Founder and CEO of Higher Medicine. “By harnessing epigenetic biology, we aim to prevent, slow, or even reverse conditions that few companies are willing to confront. Our initial focus on Kabuki syndrome is a deliberate entry point into a broader platform that can be extended to multiple high-unmet-need CNS indications such as CTE and Alzheimer’s disease. With Cerdwen’s investment, we will heighten the momentum for the seed round and accelerate toward clinical proof-of-concept.”
Leadership and Regional Validation
Higher Medicine’s leadership reflects a blend of early-stage agility and large-scale drug development experience. Dr. Kim previously served as Head of Business Planning and Operations for Haematology R&D at AstraZeneca, bringing operational and strategic depth from big pharma into the company’s rare disease focus.
In addition to private capital, the company has also received earlier support from the Maryland Technology Development Corporation (TEDCO) through its Pre-Seed Builder Fund, adding a layer of public-sector validation as the company transitions toward clinical readiness.
The Cerdwen investment also reflects the connective tissue of the Mid-Atlantic biotech ecosystem. The partnership emerged through the Mid-Atlantic Diamond Venture (MADV), which convenes founders and investors through quarterly forums.
“This investment represents a strong validation of Higher Medicine’s scientific vision and execution,” said Marie Mazur, Board Member of MADV. “It also highlights the power of MADV’s regional biotech network and quarterly Forums, as this partnership originated from our December pitch event.”
Why It Matters
Rare pediatric and neurodegenerative disorders remain among the most scientifically complex and capital-intensive areas in biopharma, often leaving patients with limited or purely supportive treatment options. Higher Medicine’s strategy—advancing clinically informed small molecules with known safety profiles—aims to compress timelines and reduce development risk at a stage where many programs stall.
From an ecosystem standpoint, the company’s progress underscores the role of targeted strategic investors and state-backed funding in helping early neurotherapeutics companies bridge the gap between discovery and first-in-human trials. It also reflects continued investor confidence in the Mid-Atlantic region as a source of differentiated CNS innovation.
As Higher Medicine moves toward IND-enabling milestones and its first clinical studies, the latest investment marks more than incremental financing—it signals growing alignment around a platform designed to tackle some of the brain’s most intractable diseases, starting with those that have long been overlooked.
